Simcere Pharmaceutical Group Limited
2096
Rank in Stocks
#4481
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the... Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-AĆ). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
Share Price
$1.32
Market Cap
$3.40B
Change (1 day)
-4.51%
Change (1 year)
-19.88%
Country
CN
Trade Simcere Pharmaceutical Group Limited (2096)
Category
Healthcare
P/E ratio for Simcere Pharmaceutical Group Limited (2096)
P/E ratio as of October 2026 TTM: 14.48
According to Simcere Pharmaceutical Group Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.48. At the end of 2024 the company had a P/E ratio of 22.99.
P/E ratio history for Simcere Pharmaceutical Group Limited from 2012 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 14.48 | -27.29% |
| 2025 | 19.91 | -13.41% |
| 2024 | 22.99 | 4.45% |
| 2023 | 22.02 | -23.51% |
| 2022 | 28.78 | 127.11% |
| 2021 | 12.67 | -56.80% |
| 2020 | 29.34 | 15.20% |
| 2019 | 25.47 | -25.59% |
| 2018 | 34.22 | -49.64% |
| 2017 | 67.96 | 308.19% |
| 2012 | 16.65 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | 98.83% |
US
|
|
| -28.36 | -295.90% |
US
|
|
| -25.99 | -279.55% |
AU
|
|
| 31.22 | 115.65% |
NL
|
|
| 17.49 | 20.82% |
BE
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.